...
首页> 外文期刊>Biological trace element research >Depressed antioxidant status in pregnant women on iron supplements: pathologic and clinical correlates.
【24h】

Depressed antioxidant status in pregnant women on iron supplements: pathologic and clinical correlates.

机译:孕妇补充铁剂后的抗氧化剂状态降低:病理和临床相关。

获取原文
获取原文并翻译 | 示例

摘要

Iron (Fe) remains a commonly prescribed supplement in pregnancy. Its possible pathologic potential is either uncommonly considered or ignored. We determined the antioxidant status in pregnant women with and without Fe supplements. Fifty-eight apparently healthy pregnant women on Fe supplements were selected for the study from the antenatal clinic of the University College Hospital, Ibadan, Nigeria. Fifty-five aged matched pregnant women who were not on Fe from various parishes of the Christ Apostolic Church, Ibadan (non-drug using Christian sect) were randomly selected as controls. Both groups were classified according to the trimesters of pregnancy. The gestational age in both pregnant women on Fe supplements and non-supplement pregnant women was similar. Fruit and vegetables consumption was higher in the supplement than in the non-supplement group (57.2% vs. 37.3%). Anthropometric indices, weight, height, and BMI, were also similar. But while the weight of the Fe supplement group decreased by nearly 3% in the third trimester, it increased by over 10% (p < 0.00) in the non-supplement group in the same period. Serum Fe level was significantly higher in the supplement than the non-supplement group (p < 0.001). In contrast, the levels of the antioxidants, ascorbic acid, copper (Cu), zinc (Zn), and bilirubin were all significantly decreased (p < 0.05, p < 0.001, p < 0.05, and p < 0.05, respectively). Uric acid level though also lower in the supplement group did not reach statistical significance (p > 0.05), while vitamin E was similar in both groups. There was relative stability of all antioxidants except uric acid, which declined from the first to the last trimester in the non-supplement group. The significantly higher Fe level in the second trimester was sustained in the third trimester though to a lesser degree (p < 0.05) and associated with significant decreases in the following antioxidant levels in the supplement group, ascorbic acid, bilirubin, Cu, and Zn (p < 0.02, p < 0.02, p < 0.02, and p < 0.001, respectively). Uric acid and vitamin E though lower in the supplement group were not significantly different. Remarkably, percentage changes between the first and third trimesters revealed that serum Fe increased by over 116% in the Fe supplement group, while it only increased by over 50% in the non-supplement group. This was associated with 23.50% decrease in ascorbate level (p < 0.003) in the supplement group, while it decreased by only 3.70% in the non-supplement group (p > 0.05). Again vitamin E decreased by 17.22% in the supplement group, while it decreased by only 7.30% in the non-supplement group during the period. Uric acid and bilirubin levels decreased by similar proportions during the period, while Zn decreased by 18.55% in the supplement group and by 14.86% in the non-supplement group. In contrast Cu increased by 7.20% in the supplement group, while it increased by only 2.96 in the non-supplement group. Additionally, all the antioxidants in the supplement group except vitamin E, viz, ascorbic acid, bilirubin, Cu, uric acid, and Zn, were significantly inversely correlated with serum Fe level (r - 0.299, p < 0.05, r - 0.278, p < 0.05, r - 0.383, p < 0.05, and r - 0.0369, p < 0.05). These data imply markedly depressed antioxidant status in the Fe supplement pregnant group with attendant oxidative stress (most probably pro-oxidant Fe-induced). This is associated with molecular and cellular damage as well as a number of pathologic and clinical correlates that underlie the exacerbation of morbidity and mortality in maternal and child populations, particularly in the developing countries. This appears to call for serious caution and prior evaluation of antioxidant and Fe status and during the use of Fe supplements in pregnancy for monitoring and prognostic purposes and to avert or ameliorate oxidative stress-induced pathologies in maternal and fetal systems.
机译:铁(Fe)仍然是孕妇常用的处方补品。不常见地考虑或忽略了其可能的病理潜能。我们确定了有和没有铁补充剂的孕妇的抗氧化剂状态。从尼日利亚伊巴丹大学学院医院的产前诊所中选择了58名健康补充铁的表面健康孕妇。随机选择了来自伊巴丹基督使徒教堂各教区的非铁中的55名年龄匹配的孕妇(使用基督教教派的非药物)作为对照。两组均根据妊娠中期进行分类。补充铁和不补充铁的孕妇的胎龄相似。补充剂中水果和蔬菜的摄入量高于非补充剂组(57.2%比37.3%)。人体测量指标,体重,身高和BMI也相似。但是,尽管补铁组的重量在孕晚期减少了近3%,但同期非补铁组增加了10%以上(p <0.00)。补品中的血清铁水平显着高于非补品组(p <0.001)。相反,抗氧化剂,抗坏血酸,铜(Cu),锌(Zn)和胆红素的含量均显着降低(分别为p <0.05,p <0.001,p <0.05和p <0.05)。补充剂组中的尿酸水平虽然也较低,但未达到统计学显着性(p> 0.05),而两组中的维生素E相似。除尿酸外,所有抗氧化剂均具有相对稳定性,而尿酸在非补充组中从头三个月开始下降。尽管妊娠中期的铁水平较低(p <0.05),但妊娠中期的铁水平明显升高,并且在补充剂组抗坏血酸,胆红素,铜和锌中,其随后的抗氧化剂水平显着降低( p <0.02,p <0.02,p <0.02和p <0.001)。补充剂组中的尿酸和维生素E含量较低,但无显着差异。值得注意的是,孕中期和孕中期之间的百分比变化表明,补铁组的血清铁增加了116%以上,而无补铁组的血清铁仅增加了50%以上。补充剂组的抗坏血酸水平降低了23.50%(p <0.003),而非补充剂组的抗坏血酸水平仅降低了3.70%(p> 0.05)。在此期间,补充剂组的维生素E再次下降了17.22%,而非补充剂组的维生素E仅下降了7.30%。在此期间,尿酸和胆红素水平下降了相似的比例,而补品组中的锌下降了18.55%,非补品组中的锌下降了14.86%。相反,补品组中的铜增加了7.20%,而补品组中的铜仅增加了2.96。此外,除维生素E,即维生素E,抗坏血酸,胆红素,铜,尿酸和锌外,补充剂组中的所有抗氧化剂与血清铁水平呈显着负相关(r-0.299,p <0.05,r-0.278,p <0.05,r-0.383,p <0.05,和r-0.0369,p <0.05)。这些数据表明,在补充铁的怀孕组中,伴随着氧化应激(最可能是由铁引起的前氧化剂)的抗氧化剂状态明显降低。这与分子和细胞损伤以及许多病理和临床相关性有关,这些相关性是母婴特别是发展中国家母婴发病率和死亡率加剧的基础。这似乎需要认真谨慎并事先评估抗氧化剂和铁的状态,并在妊娠期间使用铁补充剂进行监测和预后,并避免或改善母体和胎儿系统中氧化应激诱导的病理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号